Table 5. Single arm meta-analysis for ORR in each treatment according to PD-L1 expression subgroup.

Treatment	ORR	95% CI (lower)	95% CI (upper)
PD-L1 ≥50%
Chemo	0.35	0.32	0.37
Nivo	0.45	0.39	0.51
Nivo + Ipi	0.44	0.38	0.51
Atez	0.38	0.29	0.48
Atez + Chemo	0.64	0.54	0.75
Pembro	0.42	0.38	0.47
Pembro + Chemo	0.63	0.56	0.70
PD-L 1–49%
Chemo	0.32	0.29	0.34
Nivo	0.36	0.31	0.41
Nivo + Ipi	0.27	0.20	0.33
Atez + Chemo	0.47	0.40	0.55
Pembro	0.16	0.12	0.20
Pembro + Chemo	0.52	0.46	0.58
PD-L1 positive
Chemo	0.33	0.31	0.35
Nivo	0.40	0.36	0.44
Nivo + Ipi	0.36	0.31	0.41
Atez	0.29	0.24	0.35
Atez + Chemo	0.52	0.46	0.58
Pembro	0.27	0.24	0.31
Pembro + Chemo	0.56	0.50	0.62
PD-L1 negative
Chemo	0.29	0.26	0.32
Nivo + Chemo	0.38	0.31	0.45
Nivo + Ipi	0.27	0.21	0.34
Atez + Chemo	0.44	0.38	0.50
Pembro + Chemo	0.47	0.41	0.54

Chemo, chemotherapy; Carem + Chemo, caremlizumab plus chemotherapy; Nivo, nivolumab; Nivo + Ipi, nivolumab plus ipilimumab; Nivo + Chemo, nivolumab plus chemotherapy; Atez, atezolizumab; Atez + Chemo, atezolizumab plus chemotherapy; Pembro, pembrolizumab; Pembro + Chemo, pembrolizumab plus chemotherapy; ORR, objective response rate; PD-L1, programmed death ligand 1.